328
- Lobaton T, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory
bowel disease. Aliment Pharmacol Ther. 2015;42(4):441–51. - Desai A, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy
in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309–15. - Ha C, Katz S. Management of inflammatory bowel disease in the elderly: do biologicals offer
a better alternative? Drugs Aging. 2013;30(11):871–6. - Katz S, Surawicz C, Pardi DS. Management of the elderly patients with inflammatory bowel
disease: practical considerations. Inflamm Bowel Dis. 2013;19(10):2257–72. - Kennedy NA, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel
disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol
Ther. 2016;43(8):910–23. - Gisbert JP, Marin AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in
inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016;
111(5):632–47. - Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor alpha therapy in
inflammatory bowel disease. World J Gastroenterol. 2015;21(16):4773–8. - de Suray N, et al. Close monitoring of CRP and fecal calprotectin is able to predict clini-
cal relapse in patients with Crohn’s disease in remission after infliximab withdrawal. A sub-
analysis of the Stori study. Gastroenterology. 2012;142(5):S149. - Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unneces-
sary toys? Gut. 2006;55(3):426–31. - Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev.
Gastroenterol Hepatol. 2010;7(2):110–7.
L. Zhu and G.Y. Melmed